Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Vaginal Neoplasms 1Lymphoma, Follicular 1Glioblastoma 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

Temozolomide 24Radiotherapy 10Magnetic Resonance Spectroscopy 10Radiation 8Specimen Handling 7Lomustine 5Bevacizumab 4Nivolumab 3Biopsy 3Aminolevulinic Acid 3veliparib 2trametinib 2olaparib 2lutetium Lu 177 dotatate 2dabrafenib 2cemiplimab 2azeliragon 2Surgical Procedures, Operative 2Receptors, Interleukin-8B 2Photons 2Palliative Care 2Ipilimumab 2D2C7-(scdsFv)-PE38KDEL 2Carboplatin 2CTLA-4 Antigen 2vocimagene amiretrorepvec 1varlilumab 1ulixertinib 1tinostamustine 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 30 days × Clear all
NCT06860594 2026-06-05

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡